SUMMARY Previous open studies have suggested that felodipine, a selective calcium antagonist and vasodilator, may be useful in the treatment of heart failure. A double blind placebo controlled crossover trial was therefore conducted to investigate the clinical and haemodynamic effects of felodipine in 15 patients with chronic ischaemic heart failure in New York Heart Association symptom class III. Felodipine significantly increased resting and exercise (25 W bicycle ergometry) cardiac output without producing concomitant changes in resting or exercise heart rate or right and left ventricular filling pressures. Felodipine did not significantly improve symptom scores or exercise capacity in the group as a whole. It also resulted in significant fluid retention as shown by a rise in ankle circumference, body weight, and a fall in haematocrit.
Further research is required to elucidate the mechanism that is responsible for the discrepancy between the haemodynamic and clinical effects of felodipine in patients with moderately severe heart failure.
The ability of peripheral vasodilators to improve cardiac performance in cardiac failure has been well documented.l This, together with the compelling theoretical reasons that support their use, [4] [5] [6] [7] [8] implies that vasodilators are now accepted as a viable treatment option in the management of heart failure. Some vasodilators have also been shown to improve the functional status9 -12 and prognosis1 3 of patients with heart failure. The calcium antagonists as a class of vasodilator, however, have not been widely accepted as a treatment option in heart failure largely because of their negative inotropic effects.
Felodipine is a new calcium antagonist vasodilator with negligible negative inotropic properties.14 It has been shown in open studies to produce beneficial haemodynamic effects151-7 and improvements in the functional capacity of patients in congestive heart failure.18 The aim of this study was to establish whether these preliminary results were borne out in a double blind placebo controlled crossover trial.
Requests for reprints to Dr L B Tan, Cardiac Department, John Radcliffe Hospital, Headington, Oxford OX3 9DU.
Accepted for publication 9 March 1987 Patients and methods
PATIENT POPULATION
We studied 15 
PROCEDURES

Clinical assessments
At each visit the patient was asked to assess progress from the previous visit using a scale of 1 to 7 as an indication of subjective clinical score: (1) markedly worse, (2) moderately worse, (3) slightly worse, (4) unchanged, (5) slightly improved, (6) moderately improved, and (7) markedly improved. The baseline clinical score was taken to be 4, and at each subsequent visit the score increased or decreased in a cumulative fashion depending on the degree of changes from the previous visit. Any unwanted effects were recorded at the time of each clinical assessment. Ankle circumference, measured at 10cm proximal to the medial maleolus, and body weight were also recorded at each visit. Table 2 shows the unwanted effects reported by the patients. Apart from symptoms related to vasodilation, felodipine did not appear to cause any more unwanted effects than placebo. Three patients had to have the dose of the study drug reduced because of unwanted effects when they were taking felodipine. None of the patients on placebo needed a reduction in the dose.
EXERCISE TOLERANCE TESTS
On entry into the study 12 Figure 3 shows the workload achieved and the heart rate and blood pressure at the end of symptom limited exercise. There was no significant difference in the highest workload achieved and the total work performed between patients on felodipine and on placebo. The heart rate and blood pressure at the end of exercise were also similar on felodipine and placebo. The exercise capacity at various stages during the trial when the patients were taking placebo showed no significant training effect.
HAEMATOLOGICAL AND BIOCHEMICAL RESULTS
Most standard haematological or biochemical indices did not change significantly during either of the treatment periods; however, serum potassium The cardiothoracic ratio and the size of the cardiac silhouette did not change during either of the treatment periods.
Discussion
Unlike previous studies which suggested that felodipine can produce favourable effects in heart failure'5 -18 our study did not show that this agent improved the symptoms and exercise capacity of a group of patients with chronic heart failure, despite its ability to produce desirable haemodynamic effects (as reflected by the increased cardiac index at rest and during exercise). Felodipine had considerable undesirable effects in our patients. Ankle circumference, body weight, and the fall in haematocrit showed that they retained more fluid during treatment with felodipine than with placebo.
When Emanuelsson et al studied the short term haemodynamic effects of felodipine they reported a significant decrease in heart rate and pulmonary capillary wedge pressure from baseline to postfelodipine period.'5 In a similar group of patients Timmis et al found no decrease in heart rate, but there was a large fall in pulmonary wedge pressure. 6 When we used comparable doses of felo-127 dipine (5-10mg) in a double blind study we found no significant change in either heart rate or pulmonary artery wedge pressure between baseline and post-felodipine values and between placebo and felodipine treatment. It is impossible to state whether these differences were caused by dissimilarity in patient populations studied or observer bias.
The disparity between the results obtained in this double blind study and those obtained previously in open studies underlines the importance of controlled randomised trials. This is particularly true when obtaining subjective data, such as symptoms and exercise capacity. In another open study, Timmis and colleagues reported that the exercise capacity of their patients with heart failure was improved by felodipine, 8 Hence, the longer the treatment period, the less likely was the haemodynamic assessment to be able to predict the clinical outcome. Alternatively, the study may have been too long and tolerance may be responsible for the discrepancy. This is unlikely because the haemodynamic effects have been shown to be sustained even after a longer period of treatment. 18 The dosages used may not be high enough. This is also unlikely because considerable vasodilation was observed after the administration of felodipine at the dosages given, and higher doses would be associated with worse side effects.
It may be that the wrong type of patients were studied. In conducting this study, we took great care to study a homogeneous population of patients with heart failure-they all had New York Heart Association class III heart failure caused by coronary artery disease with a left ventricular ejection fraction of 25 There is as yet no satisfactory explanation for the discrepancy between haemodynamic data and clinical findings. It is crucial to resolve this discrepancy because drug development is in part dependent on objective data obtained from haemodynamic measurements. If the results from haemodynamic evaluation cannot be related to the clinical effects of drugs, then alternative methods of assessment will have to be found, especially for the initial phases of drug development. However, before adopting this approach and rather than abandoning the practice of haemodynamic evaluation of the efficacy of vasodilator treatment, as has been suggested by Fran 
